Clinical Trial

Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer

Study acronym: MPE-NSCLC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to investigate the predictive value of exosome characteristics in patients with advanced non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE). The main question it aims to answer is: Can the long RNA profile of exosomes derived from plasma and malignant pleural effusion predict treatment response in patients with advanced NSCLC and MPE? Participants who are scheduled to receive standard systemic therapy (including immunotherapy, chemotherapy, or targeted therapy) as part of their regular medical care will be enrolled. Researchers will collect paired samples of peripheral blood and malignant pleural effusion at baseline and key time points during treatment to analyze the exosomal long RNA profiles and correlate them with treatment efficacy and survival outcomes.
Trial Details
NCT Number NCT07262671
Lead Sponsor Fudan University
Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 100 participants
Start Date 2025-10-16
Primary Completion 2027-10-16 (estimated)
Study Completion 2030-10-16 (estimated)
Updated on ClinicalTrials.gov 2025-12-04